Viewing Study NCT00216359


Ignite Creation Date: 2025-12-24 @ 2:46 PM
Ignite Modification Date: 2025-12-27 @ 9:04 AM
Study NCT ID: NCT00216359
Status: UNKNOWN
Last Update Posted: 2005-10-25
First Post: 2005-09-14
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Cohort Study for Patients Using Fuzeon (Enfuvirtide)
Sponsor: Institute for Interdisciplinary Infectiology
Organization:

Study Overview

Official Title: The Radata-Fuzeon Cohort - An Observational Cohort-Study in HIV-Infected Patients Using Fuzeon (Enfuvirtide) as Part of Their Antiretroviral Combination Therapy
Status: UNKNOWN
Status Verified Date: 2005-09
Last Known Status: ACTIVE_NOT_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The Radata-Fuzeon cohort is an observational cohort study to gain a better understanding of Fuzeon (Enfuvirtide) in daily clinical practice. Patients planned to take this drug in a new antiretroviral combination therapy (ART) are eligible to participate in this observation.

Physicians may register patients online via the internet. They are offered to get an expert advice suggesting therapeutics for a new ART.

Observation interval is every three month. However physicians are allowed to initiate new diagnostics, expert advice and therapeutic changes independently from these intervals if necessary.

Total observation time for each patients is planned for two years.
Detailed Description: None

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: